PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy

PSMA-Negative Lesion Progression Under ¹⁷⁷Lu-PSMA Radioligand Therapy

J Nucl Med. 2023 Sep;64(9):1502-1503. doi: 10.2967/jnumed.122.265099. Epub 2023 Jun 15.

¹ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California.
² Prostate Oncology Specialists, Marina Del Rey, California; and.
³ Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
⁴ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California; jcalais@mednet.ucla.edu.

No abstract available